Literature DB >> 29042227

Pathogenetic insights from quantification of the cerebriform connective tissue nevus in Proteus syndrome.

Neera R Nathan1, Rachna Patel2, Molly M Crenshaw2, Marjorie J Lindhurst2, Cara Olsen3, Leslie G Biesecker2, Kim M Keppler-Noreuil2, Thomas N Darling4.   

Abstract

BACKGROUND: The plantar cerebriform connective tissue nevus (CCTN) is the most common and problematic cutaneous manifestation of Proteus syndrome.
OBJECTIVE: To gain insights into CCTN pathogenesis and natural history.
METHODS: The size and location of plantar CCTN was measured on 152 images from 22 individuals with Proteus syndrome by 2 independent, blinded reviewers. Average measures of plantar CCTN were transformed into a linear mixed model to estimate proportionate change in size with age.
RESULTS: Median patient age was 6.9 years at study onset. The intraclass correlation coefficient between 2 blinded reviewers was 0.946 for CCTN single measures. The CCTN relative area increased with age in children (n = 18, P < .0001) by 5.6% per year. Confluent papules and nodules extending beyond the boundaries of CCTNs were gradually replaced by typical CCTN over time. The location of CCTN in different individuals overlapped near the ball of the foot. A positive relationship between CCTN growth rate and AKT1 mutant allele frequency was observed (0.62, P = .10, n = 8). LIMITATIONS: This was a retrospective review using photographs.
CONCLUSION: CCTN growth is affected by age and extent of the CCTN precursor lesion. Monitoring of CCTN size might prove useful for evaluating drug response in the treatment of Proteus syndrome. Published by Elsevier Inc.

Entities:  

Keywords:  AKT1; Proteus syndrome; cerebriform connective tissue nevus; children; natural history; overgrowth

Mesh:

Year:  2017        PMID: 29042227      PMCID: PMC5857242          DOI: 10.1016/j.jaad.2017.10.018

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  Effects of simulated genu valgum and genu varum on ground reaction forces and subtalar joint function during gait.

Authors:  Bart Van Gheluwe; Kevin A Kirby; Friso Hagman
Journal:  J Am Podiatr Med Assoc       Date:  2005 Nov-Dec

Review 2.  A genomic view of mosaicism and human disease.

Authors:  Leslie G Biesecker; Nancy B Spinner
Journal:  Nat Rev Genet       Date:  2013-05       Impact factor: 53.242

Review 3.  Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.

Authors:  Neera Nathan; Kim M Keppler-Noreuil; Leslie G Biesecker; Joel Moss; Thomas N Darling
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

Review 4.  Mosaicism in human skin. Understanding the patterns and mechanisms.

Authors:  R Happle
Journal:  Arch Dermatol       Date:  1993-11

Review 5.  Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation.

Authors:  L G Biesecker; R Happle; J B Mulliken; R Weksberg; J M Graham; D L Viljoen; M M Cohen
Journal:  Am J Med Genet       Date:  1999-06-11

6.  Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome.

Authors:  Thomas M Beachkofsky; Julie C Sapp; Leslie G Biesecker; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2010-08-14       Impact factor: 11.527

7.  Evolution of skin lesions in Proteus syndrome.

Authors:  James V Twede; Joyce T Turner; Leslie G Biesecker; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2005-05       Impact factor: 11.527

8.  Cutaneous manifestations of proteus syndrome: correlations with general clinical severity.

Authors:  Diem Nguyen; Joyce T Turner; Cara Olsen; Leslie G Biesecker; Thomas N Darling
Journal:  Arch Dermatol       Date:  2004-08

Review 9.  The categories of cutaneous mosaicism: A proposed classification.

Authors:  Rudolf Happle
Journal:  Am J Med Genet A       Date:  2015-10-22       Impact factor: 2.802

10.  AKT1 gene mutation levels are correlated with the type of dermatologic lesions in patients with Proteus syndrome.

Authors:  Marjorie J Lindhurst; Ji-An Wang; Hadley M Bloomhardt; Alison M Witkowski; Larry N Singh; David P Bick; Michael J Gambello; Cynthia M Powell; Chyi-Chia Richard Lee; Thomas N Darling; Leslie G Biesecker
Journal:  J Invest Dermatol       Date:  2013-07-24       Impact factor: 8.551

View more
  8 in total

1.  Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.

Authors:  Kim M Keppler-Noreuil; Julie C Sapp; Marjorie J Lindhurst; Thomas N Darling; Jasmine Burton-Akright; Mohammadhadi Bagheri; Eva Dombi; Ashlyn Gruber; Paul F Jarosinski; Staci Martin; Neera Nathan; Scott M Paul; Ronald E Savage; Pamela L Wolters; Brian Schwartz; Brigitte C Widemann; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2019-02-22       Impact factor: 11.025

2.  Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes.

Authors:  Kim M Keppler-Noreuil; Jasmine Burton-Akright; Marjorie J Lindhurst; Jasmine Shwetar; Julie C Sapp; Thomas Darling; Leslie G Biesecker
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-08-01

3.  A mouse model of Proteus syndrome.

Authors:  Marjorie J Lindhurst; Lauren R Brinster; Hannah C Kondolf; Jasmine J Shwetar; Miranda R Yourick; Henoke Shiferaw; Kim M Keppler-Noreuil; Gene Elliot; Cecilia Rivas; Lisa Garrett; Julio Gomez-Rodriguez; Neil J Sebire; Stephen M Hewitt; Pamela L Schwartzberg; Leslie G Biesecker
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

4.  Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.

Authors:  Emily W Modlin; Anne M Slavotinek; Thomas N Darling; Stanley Lipkowitz; Frederic G Barr; Pamela N Munster; Leslie G Biesecker; Christopher A Ours
Journal:  Am J Med Genet A       Date:  2022-04-20       Impact factor: 2.578

5.  Dermatologic findings in individuals with genetically confirmed Proteus syndrome.

Authors:  Deeti J Pithadia; Alexander M Cartron; Leslie G Biesecker; Thomas N Darling
Journal:  Pediatr Dermatol       Date:  2021-06-08       Impact factor: 1.997

6.  Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome.

Authors:  Christopher A Ours; Julie C Sapp; Mia B Hodges; Allison J de Moya; Leslie G Biesecker
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

7.  Development of the Clinical Gestalt Assessment: a visual clinical global impression scale for Proteus syndrome.

Authors:  Christopher A Ours; Mia B Hodges; Neal Oden; Julie C Sapp; Leslie G Biesecker
Journal:  Orphanet J Rare Dis       Date:  2022-04-23       Impact factor: 4.303

8.  A case report of Proteus syndrome (PS).

Authors:  Xiaoyun Zeng; Xiaoming Wen; Xinxin Liang; Lina Wang; Lingling Xu
Journal:  BMC Med Genet       Date:  2020-01-21       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.